Unicycive gets Nasdaq extension to July 7, 2025 to meet $1 bid price

Unicycive Therapeutics, Inc.

Initial non-compliance notice received July 9, 2024; 180-day cure period ended Jan 6 without compliance.
Nasdaq granted an additional 180 calendar days, until July 7, 2025, to regain $1.00 minimum bid.
Company will monitor bid price and may consider options such as a reverse stock split if needed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.